Detalhe da pesquisa
1.
Immunotherapy in resectable NSCLC: Answering the question or questioning the answer?
Cancer Cell;
42(5): 727-731, 2024 May 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38701791
2.
Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib-refractory ALK-positive NSCLC from a phase II study.
Cancer Commun (Lond);
44(4): 455-468, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38421881
3.
Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer.
Thorac Cancer;
15(5): 419-426, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38219795
4.
Clinical definition of secondary resistance to immunotherapy in non-small cell lung cancer.
Thorac Cancer;
14(34): 3421-3429, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37963454
5.
Retraction Note: Overexpressed transient receptor potential vanilloid 1 (TRPV1) in lung adenocarcinoma harbours a new opportunity for therapeutic targeting.
Cancer Gene Ther;
30(11): 1583, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37833404
6.
Cytotoxic pyridine alkaloids from a marine-derived fungus Arthrinium arundinis exhibiting apoptosis-inducing activities against small cell lung cancer.
Phytochemistry;
213: 113765, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37330031
7.
First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors.
J Hematol Oncol;
16(1): 50, 2023 05 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37158938
8.
Reprogramming of TAMs via the STAT3/CD47-SIRPα axis promotes acquired resistance to EGFR-TKIs in lung cancer.
Cancer Lett;
564: 216205, 2023 06 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-37146936
9.
Circulating tumor cells dynamics during chemotherapy predict survival and response in advanced non-small-cell lung cancer patients.
Ther Adv Med Oncol;
15: 17588359231167818, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37113733
10.
Metabolic Reprogramming Driven by IGF2BP3 Promotes Acquired Resistance to EGFR Inhibitors in Non-Small Cell Lung Cancer.
Cancer Res;
83(13): 2187-2207, 2023 07 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37061993
11.
First case report of ensartinib in a patient with metastatic ALK rearranged lung cancer with ALK I1171N mutation: a case report.
World J Surg Oncol;
21(1): 74, 2023 Mar 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36864442
12.
Gefitinib Plus Chemotherapy vs Gefitinib Alone in Untreated EGFR-Mutant Non-Small Cell Lung Cancer in Patients With Brain Metastases: The GAP BRAIN Open-Label, Randomized, Multicenter, Phase 3 Study.
JAMA Netw Open;
6(2): e2255050, 2023 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36753281
13.
Response and acquired resistance to MET inhibitors in de novo MET fusion-positive advanced non-small cell lung cancer.
Lung Cancer;
178: 66-74, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36806896
14.
Epidermal growth factor receptor inhibitors as adjuvant treatment for patients with resected non-small cell lung cancer harboring EGFR mutation: a meta-analysis of randomized controlled clinical trials.
World J Surg Oncol;
21(1): 45, 2023 Feb 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-36782320
15.
EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-mutated NSCLC: A Prospective, Randomized, Exploratory Study.
Cancer Res Treat;
55(3): 841-850, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-36791768
16.
Validation of different personalized risk models of chemotherapy-induced nausea and vomiting: results of a randomized, double-blind, phase III trial of fosaprepitant for cancer patients treated with high-dose cisplatin.
Cancer Commun (Lond);
43(2): 246-256, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36545810
17.
Neoadjuvant toripalimab combined with gemcitabine and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoTGP01): An open label, single-arm, phase Ib clinical trial.
J Exp Clin Cancer Res;
41(1): 300, 2022 Oct 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36224603
18.
The effectiveness and safety of the rapid titration strategy of background controlled-release oxycodone hydrochloride for patients with moderate-to-severe cancer pain: A retrospective cohort study.
Front Med (Lausanne);
9: 918468, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36267618
19.
Comparison of aprepitant versus desloratadine for EGFR-TKI-induced pruritus: A randomized phase 2 clinical trial.
Cancer;
128(22): 3969-3976, 2022 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36197287
20.
Case Report: Durable partial response to icotinib plus crizotinib in a lung adenocarcinoma patient with double uncommon EGFR G719D/L861Q mutations and an acquired novel CUX1-MET fusion.
Front Oncol;
12: 911362, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35957915